吸入糖皮质激素剂量与不良事件频率的关联
该观察性研究基于英国两个全国性数据集,在162,202例哮喘成人中分析短期吸入糖皮质激素(ICS)使用与12个月内不良结局的关联。结果显示低剂量ICS与不良事件无关联,而中等及以上日剂量与主要不良心脏事件、心律失常、肺栓塞和肺炎风险增加相关,但绝对风险频率较低。
要点
- 低剂量ICS短期使用未观察到与不良事件风险增加相关。
- 中等及以上日剂量ICS与心血管事件、肺栓塞和肺炎风险升高相关。
- 临床应遵循指南推荐,使用最低有效ICS剂量。
核心结论
- 短期使用低剂量ICS与不良事件无关联。
- 中等至高等日剂量ICS与心血管事件、肺栓塞和肺炎风险增加相关,但绝对风险频率较低。
研究设计与样本
- 在哮喘成人中开展的观察性研究,使用英国临床实践研究数据链Aurum和GOLD两个全国性数据集。
- 主要分析采用队列方法,以稳定逆概率治疗加权平衡暴露组与非暴露组的混杂。
- 暴露为 incident ICS 使用,结局为12个月内主要不良心脏事件(MACE)、心律失常、肺栓塞(PE)和肺炎。
- 次要分析包括巢式病例对照研究和自身对照病例系列。
- 主要队列纳入162,202例患者。
主要发现
- 日剂量201-599 μg时,MACE的HR为2.63(95%CI 1.66-4.15),心律失常2.21(95%CI 1.60-3.04),PE 2.10(95%CI 1.37-3.22),肺炎2.25(95%CI 1.77-2.85)。
- 日剂量≥600 μg时,MACE的HR为4.63(95%CI 2.62-8.17),心律失常2.91(95%CI 1.72-4.91),PE 3.32(95%CI 1.69-6.50),肺炎4.09(95%CI 2.98-5.60)。
- 较低剂量ICS与上述结局无关联。
- 次要分析结果与主要分析相似。
- 12个月ICS日剂量201-599 μg的需伤害人数(NNH):MACE 473(95%CI 344-754),心律失常567(95%CI 395-1,006),PE 1,221(95%CI 744-3,388),肺炎230(95%CI 177-327)。
关键数值与推荐
- 日剂量201-599 μg与MACE、心律失常、PE和肺炎风险增加相关(HR范围2.10-2.63)。
- 日剂量≥600 μg与上述结局风险进一步增加相关(HR范围2.91-4.63)。
- 低剂量ICS未显示与不良事件风险增加相关。
临床怎么用
- 临床医生应遵循指南推荐,使用最低有效ICS剂量以降低不良事件风险。
- 对需要中等及以上日剂量ICS的哮喘患者,应关注心血管事件、肺栓塞和肺炎的风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Inhaled corticosteroids (ICSs) are the cornerstone of asthma treatment and significantly improve morbidity and mortality. Adverse effects of oral corticosteroids are well documented, but less is known about ICS. Objectives: The aim of this study was to determine the risk of adverse effects from short-term ICS use in people with asthma. Methods: We conducted observational studies in adults with asthma using two different United Kingdom nationwide datasets: Clinical Practice Research Datalink Aurum and Clinical Practice Research Datalink GOLD. The exposure was incident ICS; the outcomes were a major adverse cardiac event (MACE), arrhythmia, pulmonary embolism (PE), and pneumonia over 12 months. Our main analyses used a cohort method with stabilized inverse probability treatment weighting to balance confounding between exposed and unexposed patients. Secondary analyses included nested case-control studies and self-controlled case series. ICS use was treated as both a categorical and a continuous variable. Absolute risk was estimated using weighted flexible parametric models. Measurements and Main Results: Among 162,202 patients in our main cohort, there was an association with all outcomes at the medium daily ICS dose or higher (hazard ratios [HRs] at 201-599 μg: MACE, 2.63 [95% confidence interval (CI), 1.66-4.15]; arrhythmia, 2.21 [95% CI, 1.60-3.04]; PE, 2.10 [95% CI, 1.37-3.22]; and pneumonia, 2.25 [95% CI, 1.77-2.85]; HRs at ≥600 μg: MACE, 4.63 [95% CI, 2.62-8.17]; arrhythmia, 2.91 [95% CI, 1.72-4.91]; PE, 3.32 [95% CI, 1.69-6.50]; and pneumonia, 4.09 [95% CI, 2.98-5.60]). There were no associations with lower doses of ICSs. Secondary analyses produced similar results. The number needed to harm using 12 months of ICS at 201 to 599 μg was as follows: MACE, 473 (95% CI, 344-754); arrhythmia, 567 (95% CI, 395-1,006); PE, 1,221 (95% CI, 744-3,388); and pneumonia, 230 (95% CI, 177-327). The number needed to harm using ICS at ≥600 μg was as follows: MACE, 224 (95% CI, 148-461); arrhythmia, 396 (95% CI, 228-1,523); PE, 577 (95% CI, 309-4,311); and pneumonia, 93 (95% CI, 69-141). Conclusions: Short-term use of low-dose ICS was not associated with adverse effects. Moderate to high daily ICS doses were associated with an increased risk, but low frequencies, of cardiovascular events, PE, and pneumonia. It is important for clinicians to adhere to guideline recommendations to use the lowest effective ICS dose.
引用
- Bloom CI, Yang F, Hubbard R, et al. Association of Dose of Inhaled Corticosteroids and Frequency of Adverse Events. Am J Respir Crit Care Med. 2025. PMID: 39088770. doi:10.1164/rccm.202402-0368OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。